clinical trial · NCT05115292
A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma
BJ Bioscience, Inc.·phase1·unknown·n = 85
Advanced Solid Tumor or LymphomaBJ-005
brief summary
This is a first-in-human, Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of BJ-005 in patients with advanced solid tumor or lymphoma. BJ-005 is a recombinant bifunctional molecule, composed of a humanized anti-PD-L1 IgG1 monoclonal antibody (mAb) fused with a portion of the extracellular domain of human TGF-β receptor II (TGF-βRII).
started
Oct 20, 2021
primary completion
Oct 20, 2024
completion
Oct 20, 2025
last updated
Nov 9, 2023
official title
A First-in-Human, Multicenter, Open-label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol